Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB)
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share, were awarded at no cost, and expire on March 30, 2036. They will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
WEINSTEIN ROBERT
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 119,170 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 119,170 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 119,170 options
Exercise price: $0.67 per share
Underlying shares: 119,170 shares
+2 more
5 metrics
Option grant size
119,170 options
Stock Option (Right to Buy) granted to director Robert Weinstein
Exercise price
$0.67 per share
Conversion or exercise price of granted stock options
Underlying shares
119,170 shares
Common Stock underlying the stock option award
Total options after grant
119,170 options
Total derivative securities held following this transaction
Option expiration date
March 30, 2036
Expiration date of Robert Weinstein’s stock options
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "0.6700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-03-30T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: "Common Stock""
annual meeting of stockholders financial
"options shall vest in full on the date of the Issuer's next annual meeting of stockholders"
FAQ
What did PharmaCyte Biotech (PMCB) disclose about Robert Weinstein?
PharmaCyte Biotech disclosed that director Robert Weinstein received a grant of 119,170 stock options. These options give him the right to buy common shares at $0.67 each if they vest and he chooses to exercise them.
How many stock options did Robert Weinstein receive from PharmaCyte (PMCB)?
Robert Weinstein received 119,170 stock options from PharmaCyte Biotech. Each option corresponds to one share of common stock and can be exercised at $0.67 per share once vested, giving him potential future equity exposure.
What is the exercise price and term of the PMCB options granted to Weinstein?
The options granted to Robert Weinstein carry an exercise price of $0.67 per share and expire on March 30, 2036. This long-dated term allows a substantial window during which he may choose to exercise if conditions are favorable.
When do Robert Weinstein’s PharmaCyte (PMCB) options vest?
Robert Weinstein’s options vest in full on the date of PharmaCyte Biotech’s next annual meeting of stockholders. Vesting is conditional on his continued service with the company through that meeting, aligning the award with ongoing board tenure.